| 慢性髓性白血病临床诊疗指南与中国实践 |
| |
| 引用本文： | 江浩,黄晓军.慢性髓性白血病临床诊疗指南与中国实践[J].中国实用内科杂志,2010,30(1):32. |
| |
| 作者姓名： | 江浩 黄晓军 |
| |
| 作者单位： | 北京大学人民医院北京大学血液病研究所; |
| |
| 基金项目： | 教育部创新团队(IRT0702) |
| |
| 摘 要： | 伊马替尼作为第一代酪氨酸激酶抑制剂,给Ph+慢性髓性白血病(CML)患者带来了革命性的疗效,NCCN及ELN将其推荐为CML的首选治疗。但伊马替尼存在治疗费用高且不能停药、产生耐药、更长期的疗效尚待观察等限制。依据我国的国情,中国CML实践推荐针对不同患者,给予TKI、HSCT、干扰素及细胞毒药物结合的个体化治疗。
|
| 关 键 词： | 慢性髓性白血病 造血干细胞移植 伊马替尼 |
Clinical practice guideline for chronic myelogenous leukemia and its practice in China |
| |
| JIANG Hao,HUANG Xiao-jun.Clinical practice guideline for chronic myelogenous leukemia and its practice in China[J].Chinese Journal of Practical Internal Medicine,2010,30(1):32. |
| |
| Authors: | JIANG Hao HUANG Xiao-jun |
| |
| Institution: | JIANG Hao,HUANG Xiao-jun.The Institute of Hematology,People\'s Hospital of Peking University,Beijing 100044,China |
| |
| Abstract: | Imatinib mesylate,as the first generation Bcr-Abl tyrosine kinase inhibitor,has brought revolutionary treatment for Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML);it has been recommended as the first-line treatment for CML by NCCN Practice Guidelines in Oncology in 2008 and European LeukemiaNet(ELN) criteria.However,imatinib has three limitations:first,it is expensive and can not be stopped if efficancy to be maintained;Second,some 20%~30% of patients develope resistance to imatini... |
| |
| Keywords: | chronic myelogenous leukemia hematopoetic stem cell transplantation imatinib |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中国实用内科杂志》浏览原始摘要信息 |
| 点击此处可从《中国实用内科杂志》下载免费的PDF全文 |
|
